Omnicorder's BioScanIR  by Szweda, Roy
QWIPM E D I C A L F O C U S
III-Vs REVIEW THE ADVANCED SEMICONDUCTOR MAGAZINE VOL 18 - NO 3 - APRIL 200536
Omnicorder’s BioScanIR 
Following on from the QWIP overview article
in the previous issue, the first developments
of QWIP technology are reaching out to com-
mercialisation. So it is exciting that the
Omnicorder Technologies’ BioScanIR
System - the world’s first biomedical appli-
cation is  based on QWIP technology - a 
classic example of ‘swords into plowshares.’
Funded by the US DoD Missile Defense
Organisation and conducted at NASA’s Jet
Propulsion Laboratory (JPL), QWIP arrays were
aimed at improvement of sensing for planetary
exploration and terrestrial surveillance. Once the
technology reached a certain stage, its potential in
non-defense applications became a real prospect.
Soon after, licenses were granted to a number of
parties interested in turning the QWIP technology
into a commercial proposition. One of these
involved the founders of Omnicorder Technologies
Inc, based in Bohemia, New York, who saw the
opportunity to acquiring an exclusive world wide
license for the commercial development of all
QWIP-based biomedical applications.
OmniCorder has since launched the world’s first
biomedical application based on QWIP technolo-
gy, the BioscanIR System, which provides func-
tional medical imaging technology for clinicians
and researchers for drug discovery, disease detec-
tion and disease management applications.
TFR spoke to Anne Marie Fields at OmniCorder
about how well European trials of the instru-
ment were confirming initial successes with
many leading medical centres in North America.
“Pilot studies at leading European hospitals are
underway.These include use of the system to
enhance surgical procedures, such as location of
perforator vessels in pre-surgical planning for
reconstructive surgery.Additionally, the system is
being tested as a post-surgical monitoring device
to ensure the continued perfusion of blood into
the new surgical flap.This represents a great
opportunity, as it is significantly more effective
and cost efficient that the current ‘pinch test’
with regard to accuracy and reproducibility.We
are also seeing great results from pilot sites, such
as the Milan Tumour Institute, that are using the
BioScanIRs to monitor cancer therapies. In addi-
tion, the BioScanIR system is successfully being
used intra-operatively during neurosurgery to
map precise tumour margins, locate seizure foci
and to ensure blood perfusion in by pass grafts.”
The instrument has much to offer medical staff
who have an outstanding need to be able to con-
tinuously monitor how successful drug and other
cancer treatments are.“Advances in cancer treat-
ment were in dire need of a reliable and easy-to-use
monitoring system.These drugs are very expensive
and do not work for every patient.Thus the clini-
cian can much more rapidly make changes to med-
ication, hence providing patient relief and saving
money. Other crucial advantages include the fact
that it is a non-contact patient-friendly portable 
system, unlike existing techniques such as PET.”
“It provides the timely detection of very minute
changes in blood perfusion.This is in complete
contrast to techniques often used today, such as
ultrasound which takes too long and is very
operator specific.”
Several key technologies have been brought
together in the BioScanIR system, not the least of
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The BioScanIR system is an
infrared-based functional
imaging system, that detects
minute changes in blood per-
fusion through the capture of
passively-emitted infrared
radiation that is produced 
by tissue.
which was the JPL-developed QWIP cam-
era technology (see III-V Review March
pg 44). In addition, and equally important,
many man-years of software development,
provide foundation for the sophisticated
algorithms that interpret the multitude of
data points generated by the system.
“Such a compact, portable unit would
simply not have been possible only a few
years ago.The measurement is very com-
putationally intensive, requiring powerful
software algorithms and hardware. It
means that a great deal of information can
be presented in a very user-friendly timely
manner, expediting diagnoses and, there-
fore, more successful treatment.”
OmniCorder Technologies has received
510K clearance from the US Food and
Drug Administration to market BioScan.
“Since then it has been used to locate
and confirm the presence of cancerous
breast lesions by detecting the cancer’s
ability to recruit a new blood supply -
one of the hallmarks of a malignant
lesion. Studies have determined that can-
cer cells exude nitric oxide.This causes
changes in blood flow and temperature
in tissue surrounding cancer, which can
then be detected by the extremely tem-
perature sensitive BioScanIR System.”
OmniCorder owns the exclusive, world-
wide licenses to use the QWIP sensor for
biological applications, including disease
detection.The sensor detects IR energy
emitted from the body and, therefore,
‘sees’ minute differences associated with
the local increase in blood flow changes.
The BioScanIR is an innovative, new
approach for rapid, non-invasive and cost-
effective imaging of therapy response. It
does not require a contrast agent, does
not use ionising radiation and does not
come into physical contact with the
patient, making it an ideal imaging tool
for the frequent imaging sessions
required for this type of treatment.
As a cancer-detection device, the detector
is sensitive to temperature differences of
less than 0.01oC and detects the slightest
rise in temperature in tissue surrounding
cancer cells.“Just like having your picture
taken with a video camera, it causes no
discomfort to the patient and uses no ion-
ising radiation. Since we announced the
BioScan System’s clearance by the FDA,
we have been inundated with requests to
install and test the unit in clinics and hos-
pitals across the country and overseas for
a variety of cancer, as well as other dis-
ease applications.”
Furthermore, the BioScanIR system has
shown great promise in coronary artery
bypass graft surgery (CABG), one of the
most frequently performed surgical proce-
dures where there is no widely- accepted,
safe, non-contact method to check the
quality of the new graft prior to closing
the patient’s chest.
“These results represent an important
milestone for quantitative assessment of
bypass grafts during CABG surgery. It is
also a very important milestone for
OmniCorder.With over a half-million of
these procedures performed every year in
the US and Europe, we think this applica-
tion represents a very significant opportu-
nity for us to improve surgical outcomes
and reduce healthcare delivery costs.”
Cancer treatment monitor
For the future, the BioScan System is also
being evaluated as a monitoring device
during cancer treatment. At the Milan
Tumour Institute and The Cleveland
Clinic the system is being used to 
monitor neoadjuvant breast cancer thera-
py. This approach, which involves admin-
istering drug therapy prior to surgery,
seeks to reduce tumour size and improve
a patient’s chance for less-invasive, breast
conserving surgery.A potential advantage
of neoadjuvant cancer therapy is
improved, disease-free, overall survival.
Critical to successful implementation of
this approach is a means to detect
patients’ response to therapy and to
monitor its continued effect.
At the Dana-Farber Cancer Institute in
Boston, MA, a new class of anti-cancer
products, designed specifically to inhibit
the growth of cancer by greatly reducing
the blood supply to it, were tested, pub-
lished and presented. Doctors are using
BioScanIR to detect important treatment-
induced changes in an array of cancerous
lesions of breast and skin, among others.
The BioScanIR System is now being tri-
alled in Europe, with the latest installa-
tion at the Karolinska Institute in
Stockholm where clinicians began using
the system for the assessment and grad-
ing of skin cancer, to evaluate radiation
therapy’s impact on microcirculation
within breast tissue, and to assess the
effectiveness of peripheral vascular
wound healing therapies.
Email: info@omnicorder.com 
Web: www.omnicorder.com
QWIP M E D I C A L F O C U S
www.three-fives.com 37
A close up of the camera head and display screen with a raw data image displayed.
